Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials

Kathleen M Andersen; Jonathan T L Cheah; Lyn March; Susan J Bartlett; Dorcas Beaton; Clifton O Bingham; Peter M Brooks; Robin Christensen; Philip G Conaghan; Maria-Antonietta D'Agostino; Maarten de Wit; Amylou C Dueck; Susan M Goodman; Shawna Grosskleg; Catherine L Hill; Martin Howell; Sarah L Mackie; Bethan Richards; Beverly Shea; Jasvinder A Singh; Vibeke Strand; Peter Tugwell; George A Wells; Lee S Simon

doi:10.3899/jrheum.181123

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials

Kathleen M Andersen, Jonathan T L Cheah, Lyn March, Susan J Bartlett, Dorcas Beaton, Clifton O Bingham, Peter M Brooks, Robin Christensen, Philip G Conaghan, Maria-Antonietta D'Agostino, Maarten de Wit, Amylou C Dueck, Susan M Goodman, Shawna Grosskleg, Catherine L Hill, Martin Howell, Sarah L Mackie, Bethan Richards, Beverly Shea, Jasvinder A SinghVibeke Strand, Peter Tugwell, George A Wells, Lee S Simon

Parker Instituttet

9 Citationer (Scopus)

Abstract

OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases.

METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.

RESULTS: Five themes pertaining to drug safety measurement emerged.

CONCLUSION: Current approaches have failed to include data from the patient's perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.

Originalsprog	Engelsk
Tidsskrift	Journal of Rheumatology
Vol/bind	46
Udgave nummer	8
Sider (fra-til)	1053-1058
Antal sider	6
ISSN	0315-162X
DOI	https://doi.org/10.3899/jrheum.181123
Status	Udgivet - aug. 2019

Adgang til dokumentet

10.3899/jrheum.181123

Andre filer og links

Link to publication in Scopus

Citationsformater

Andersen, K. M., Cheah, J. T. L., March, L., Bartlett, S. J., Beaton, D., Bingham, C. O., Brooks, P. M., Christensen, R., Conaghan, P. G., D'Agostino, M.-A., de Wit, M., Dueck, A. C., Goodman, S. M., Grosskleg, S., Hill, C. L., Howell, M., Mackie, S. L., Richards, B., Shea, B., ... Simon, L. S. (2019). Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. Journal of Rheumatology, 46(8), 1053-1058. https://doi.org/10.3899/jrheum.181123

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. / Andersen, Kathleen M; Cheah, Jonathan T L; March, Lyn et al.
I: Journal of Rheumatology, Bind 46, Nr. 8, 08.2019, s. 1053-1058.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Andersen, KM, Cheah, JTL, March, L, Bartlett, SJ, Beaton, D, Bingham, CO, Brooks, PM, Christensen, R, Conaghan, PG, D'Agostino, M-A, de Wit, M, Dueck, AC, Goodman, SM, Grosskleg, S, Hill, CL, Howell, M, Mackie, SL, Richards, B, Shea, B, Singh, JA, Strand, V, Tugwell, P, Wells, GA & Simon, LS 2019, 'Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials', Journal of Rheumatology, bind 46, nr. 8, s. 1053-1058. https://doi.org/10.3899/jrheum.181123

@article{cb591102def249aaa7bca538974d92de,

title = "Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials",

abstract = "OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases.METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.RESULTS: Five themes pertaining to drug safety measurement emerged.CONCLUSION: Current approaches have failed to include data from the patient's perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.",

keywords = "Clinical trials disease-modifying antirheumatic drugs, OMERACT, Patient satisfaction, Risk assessment",

author = "Andersen, {Kathleen M} and Cheah, {Jonathan T L} and Lyn March and Bartlett, {Susan J} and Dorcas Beaton and Bingham, {Clifton O} and Brooks, {Peter M} and Robin Christensen and Conaghan, {Philip G} and Maria-Antonietta D'Agostino and {de Wit}, Maarten and Dueck, {Amylou C} and Goodman, {Susan M} and Shawna Grosskleg and Hill, {Catherine L} and Martin Howell and Mackie, {Sarah L} and Bethan Richards and Beverly Shea and Singh, {Jasvinder A} and Vibeke Strand and Peter Tugwell and Wells, {George A} and Simon, {Lee S}",

year = "2019",

month = aug,

doi = "10.3899/jrheum.181123",

language = "English",

volume = "46",

pages = "1053--1058",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "8",

}

TY - JOUR

T1 - Improving Benefit-harm Assessment of Therapies from the Patient Perspective

T2 - OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials

AU - Andersen, Kathleen M

AU - Cheah, Jonathan T L

AU - March, Lyn

AU - Bartlett, Susan J

AU - Beaton, Dorcas

AU - Bingham, Clifton O

AU - Brooks, Peter M

AU - Christensen, Robin

AU - Conaghan, Philip G

AU - D'Agostino, Maria-Antonietta

AU - de Wit, Maarten

AU - Dueck, Amylou C

AU - Goodman, Susan M

AU - Grosskleg, Shawna

AU - Hill, Catherine L

AU - Howell, Martin

AU - Mackie, Sarah L

AU - Richards, Bethan

AU - Shea, Beverly

AU - Singh, Jasvinder A

AU - Strand, Vibeke

AU - Tugwell, Peter

AU - Wells, George A

AU - Simon, Lee S

PY - 2019/8

Y1 - 2019/8

N2 - OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases.METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.RESULTS: Five themes pertaining to drug safety measurement emerged.CONCLUSION: Current approaches have failed to include data from the patient's perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.

AB - OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases.METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.RESULTS: Five themes pertaining to drug safety measurement emerged.CONCLUSION: Current approaches have failed to include data from the patient's perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.

KW - Clinical trials disease-modifying antirheumatic drugs

KW - OMERACT

KW - Patient satisfaction

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=85070210298&partnerID=8YFLogxK

U2 - 10.3899/jrheum.181123

DO - 10.3899/jrheum.181123

M3 - Journal article

C2 - 30647191

SN - 0315-162X

VL - 46

SP - 1053

EP - 1058

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 8

ER -

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater